$NOW & $CRM have a very a specific window (next 12 to 18 months) where the software companies with deepest customer data & most embedded workflow integrations can consolidate the agentic layer before the AI startups build simpler, faster alternatives have the distribution to displace them.
Buy or sell guide
Should I Buy CRM Stock Right Now?
A fast read on Wall Street conviction, live analyst commentary on X, and current valuation context for Salesforce, Inc..
Updated 2026-05-06
Wall Street currently rates CRM buy with a 12-month price target of $287 (+53.5% upside). See live commentary from high-reach stock analysts on X, plus the bull case, key risks, and the latest earnings execution.
Wall Street
Buy97 analystsConsensus target
$287 target (+53.5%)Current price $186.99Analyst sentiment
Bullish from 3 recent analyst posts2 bull · 0 bear · 1 neutralEarnings context
EPS beat 24.9%Reported Wed Feb 25Wall Street verdict
Should I Buy CRM Stock? Here's What Analysts Think
97 analysts currently cover CRM. Below is their consensus rating, price target range, and implied upside.
According to 97 analysts, Salesforce, Inc. (CRM) is rated Buy with a consensus 12-month price target of $287 — representing 53% upside from today's price of $187. The bull case target is $400, the bear case is $235.
CRMBuy
From 97 analyst ratings- Current price
- $186.99
- Consensus Target
- $287 (+53.5% upside)
- Forward P/E
- 15.9x
- Coverage
- 97 analyst ratings
High target$400
Low target$235
At $186.99, the consensus setup implies +53.5% versus the 12-month target.
- 74 of 97 analysts lean Buy or Strong Buy, while 21 stay on Hold and 2 lean bearish.
- CRM trades at roughly 15.9x forward earnings, so the bull case still depends on growth staying strong.
- Analysts span a wide range from $235 to $400, so conviction matters as much as the consensus target.
Below, compare that institutional answer with the live analyst commentary on X for CRM right now.
1 of 2 analysts cut targetsBTIG $255Piper Sandler $215
May 2026Live commentary on X· Last 14 days · 3 takes
What Analysts Are Saying About Salesforce, Inc. Right Now
Real posts from high-reach stock analysts mentioning CRM, shown exactly as written. Sorted by engagement — most discussed first.
Recent high-reach analyst commentary leans bullish — the loudest voices on X are giving the tape the benefit of the doubt.
Bullish·
2 Bullish1 Neutral0 Bearish
CRM goes higher, NOW? why not, money out of AI into SAAS courtesy the WSJ
"Sales" were never the problem $CRM https://t.co/FRSCyNdd4W
Posts sourced from high-follower stock analysts on X. Bullish/bearish signals are auto-classified; verify on the original post before acting.
Should you buy CRM?
Is CRM a Buy, Hold, or Sell Right Now?
A structured look at the bull case, the risks, and the most recent earnings execution for CRM before you decide whether to buy, hold, or sell.
Current setup
CRM beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.
Bull Case
What keeps the long thesis intact
- Undervalued with Strong Growth PotentialSalesforce is considered undervalued with significant upside potential, boasting a three-year CAGR in the top 10% of its industry.
- AI Leadership and Product MomentumSalesforce's AI products like Agentforce and Data Cloud are experiencing explosive growth, expected to drive future revenue reacceleration.
- Strategic Acquisitions and PartnershipsRecent acquisitions such as Slack and Informatica, along with partnerships like Workday, enhance Salesforce's ecosystem and market position.
- Strong Financials and Balance SheetThe company shows continued growth in revenue, EPS, and free cash flow, with an underleveraged balance sheet providing financial flexibility.
- Positive Analyst SentimentA majority of analysts rate Salesforce as a 'Buy' or 'Strong Buy,' with price targets suggesting upside to as high as $500 per share.
- Meeting the 'Rule of 40'Salesforce meets the industry's 'Rule of 40,' indicating a balance of profitable growth with accelerating revenue and strong margins.
Wall Street rates CRM buy, giving the bull case institutional backing from 97 analysts.
Watch Out For
What can break the setup quickly
- Increased CompetitionThe enterprise software market, especially in AI, is becoming more competitive, potentially challenging Salesforce's market share.
- Slowing Revenue GrowthConcerns exist about sustaining high growth rates, as revenue growth contracted in the past fiscal year according to some analyses.
- High Costs and Complex PricingSalesforce's high costs and complex pricing structure may hinder smaller companies from fully benefiting from its solutions.
- Integration Risks from AcquisitionsUncertainties about costs and financial impacts arise as Salesforce continues to integrate new companies and technologies.
- Potential for Disruption by Cloud HyperscalersMajor cloud providers could disrupt standalone enterprise software providers like Salesforce by bundling AI, storage, and security.
- Valuation ConcernsSome analyses suggest the current price may be over-inflated due to high growth expectations, raising valuation concerns.
Watch whether new negative commentary on CRM points to these structural risks or is simply reacting to short-term price moves.
CRM Earnings Reaction — What the Last Quarter Showed
Last Quarter
- EPS
- $3.81 vs $3.05 est.Beat 24.9%
- Revenue
- $11.2B vs $11.2B est.Beat 0.1%
Full CRM Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy CRM Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See CRM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare with Peers
Compare business quality, growth, and profitability against top sector peers.
Start ComparisonCRM — Frequently Asked Questions
Quick answers to the most common questions about buying CRM stock.
Should I buy CRM stock right now?
Verdict
CRM looks attractive at current levels — Wall Street's consensus rating is "Buy" with a $287 price target (+53.5% upside from $186.99). The council of high-follower analysts on X is currently signalling bullish. This is informational only — verify the data and consider your own risk tolerance before deciding.
Is now a good time to buy CRM?
Timing
Timing depends on your horizon, but the data signals are: consensus rating "Buy" with +53.5% upside to the $287 target. In the past 30 days, 1 of 2 covering analysts cut their price targets — a bearish signal.
What is the price target for CRM stock?
Price Target
CRM's consensus 12-month price target is $287, set by 97 Wall Street analysts. The bull case high is $400 and the bear case low is $235. From the current price of $186.99, this implies +53.5% upside.
Is CRM overvalued or undervalued?
Valuation
CRM appears undervalued — the $287 consensus target is +53.5% above today's $186.99. It trades at a forward P/E of 15.9x. Targets range from $235 (bear) to $400 (bull), reflecting different assumptions about growth and margins.
Should I buy CRM before earnings?
Earnings
CRM reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $287 target. Consider position sizing rather than going all-in pre-print.
What are analysts saying about CRM stock?
Coverage
Of 97 analysts covering Salesforce, Inc. (CRM): 2 Strong Buy, 72 Buy, 21 Hold, 2 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $287 (range $235–$400). Bullish analysts outnumber bearish by more than 2-to-1.
What are the risks of buying CRM stock?
Risks
2 of the 97 analysts covering CRM rate it Sell or Strong Sell. Common concerns include valuation stretch, slowing growth, and sector-specific headwinds — see the Bull vs. Risk cards above for the specific theses on Salesforce, Inc..
This page is for informational purposes only and does not constitute financial advice. Always conduct your own research before investing.